Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Noxopharm Ltd V.NOX


Primary Symbol: NOXOF

Noxopharm Limited is a biotech company. It is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. It utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA vaccine enhancement). Chroma is a technology platform focused on the development of multiple drug candidates, primarily for cancer treatment. The Sofra technology platform has a pipeline of proprietary drugs based on oligonucleotides, the building blocks of deoxyribonucleic acid (DNA), with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-VAC has applications in the treatment of excessive inflammatory responses associated with specialized inflammatory receptors in the body known as Toll-like receptor 7.


OTCPK:NOXOF - Post by User

Post by MrMonkon Jun 21, 2013 1:00pm
146 Views
Post# 21555559

Updated 43-101

Updated 43-101

 

Yes I am well aware of the timing issue. I think MDA in Reno have done a very thorough job and building a 3-D model with complex geology is no easy task. However, you would think they/us could have estimated the time better. Don’t shoot me I’m only the messenger. J

Dale

From: Mr. Monk
Sent: Friday, June 21, 2013 9:16 AM
To: Dale Paruk, NioGold Mining
Subject: Re: Aurizon/Hecla

Dale,

Yes, I understand these things take time - I'm not in the mining business but I am a business owner and I understand the timeline for business matters.

I think shareholder expectations may have been mismanaged by noting that results would be out in April.  This feedback is meant to be purely constructive.

Have a good weekend,

M

On 2013-06-21, at 12:05 PM, Dale Paruk, NioGold Mining wrote:

Soon. Part of the timing requires feedback from Hecla. These things take time, both in evaluating the data and then the various drafting and  approvals of news releases.

Dale Paruk

From: Mr. Monk

Sent: Friday, June 21, 2013 8:53 AM

To: Dale Paruk
Subject: Re: Aurizon/Hecla

Hi Dale,

How can it possibly take this long for the updated resource calculation?  You were hoping for early April - it's now 2 1/2 months later.  When are we going to get this?

M

On 2013-03-04, at 10:55 PM, Dale Paruk wrote:

We don’t know and don’t expect contact with Hecla for a few months until they sort out the ARZ deal. We heard Alamos is not likely  to counter with a higher offer. Assuming Hecla wins, we will have to see how they respond to us over the summer. As you rightly mention, September is coming fast and if they don’t make a decision, we retain 100%. There certainly is interest in our property from others in the neighbourhood. Things could get interesting when we release the phase 2 resource calculation hopefully in early April. All looks good for NOX.

Thanks,

Dale

 

<< Previous
Bullboard Posts
Next >>